The Hospital will use the SOPHiA DDM™ Platform
to advance its research and diagnosis of blood cancers
BOSTON and ROLLE,
Switzerland, Aug. 17,
2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that A.O.U. San Giovanni di Dio
Ruggi d'Aragona is now utilizing the SOPHiA DDM™ Platform to
advance its research and diagnosis of blood cancers, specifically
Myeloma. The hospital, located on the western coast of Italy in Salerno, also leverages SOPHiA
GENETICS technology to review rare and inherited disorders.
Blood cancers represent the fourth most frequent cancer type in
the developed world,1 with Myeloma being one of the
three main types of blood cancer. As with most hematologic
malignancies, next-generation sequencing (NGS), which produces a
vast amount of data, is often preferred to aid in the diagnosis and
treatment planning of Myeloma as it provides detailed information
on the genome. The implementation of SOPHiA GENETICS technology
will aid the A.O.U. San Giovanni di Dio Ruggi d'Aragona
Hematology Unit in using NGS testing for the first time. The
introduction of this new technology will provide the hospital with
an increased amount of data and is expected to support the
advancement of clinical research, diagnosis and treatment.
"We have seen a shift in the sequencing landscape with more and
larger data sets becoming readily available. With that shift, the
need for accurate and timely data analysis is becoming increasingly
important to ensure that our customers, like A.O.U. San Giovanni di
Dio Ruggi d'Aragona, can still find important biomarkers to
research disorders and diagnose their patients. At SOPHiA
GENETICS, we are able to contribute to that accurate and timely
data analysis through our SOPHiA DDM™ Platform to support our
customers in their endeavor towards precision medicine," said Kevin
Puylaert, Managing Director, EMEA, SOPHiA GENETICS. "We are excited
to see A.O.U. San Giovanni di Dio Ruggi d'Aragona pave the way for
data-driven medicine in Salerno, Italy."
The SOPHiA DDM™ Platform, which is a cloud-based platform that
uses Artificial Intelligence (AI) and machine learning to
analyze and interpret raw data files from NGS, will help
A.O.U. San Giovanni di Dio Ruggi d'Aragona quickly sort a large
volume of raw NGS data. The SOPHiA DDM™ Platform also aids in
faster data analysis and streamlined insights, enabling clinical
researchers to make data-based treatment recommendations more
easily.
In addition to providing a simplified bioinformatics
workflow, the SOPHiA DDM™ Platform will allow A.O.U. San Giovanni
di Dio Ruggi d'Aragona to retain ownership of its database,
supporting the research team as it continues to increase its
expertise.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram. Where
others see data, we see answers.
SOPHiA DDM™ Dx MYS is available as a CE-IVD product for
In Vitro Diagnostic Use in Europe,
Turkey and Israel. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains
statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products, and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management's beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1
https://www.lls.org/facts-and-statistics/facts-and-statistics-overview
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aou-san-giovanni-di-dio-ruggi-daragona-expands-usage-of-sophia-genetics-ddm-platform-301903610.html
SOURCE SOPHiA GENETICS